Semaglutide vs Tirzepatide: Wegovy, Ozempic, Zepbound and Mounjaro Compared
Semaglutide vs tirzepatide for weight loss and diabetes: mechanism, trial results, head-to-head data, labels, side effects, cost and which option fits which case.
- Published
- May 18, 2026
- Last reviewed
- May 18, 2026
- Reading time
- 5 min read
Semaglutide and tirzepatide are the two names people compare most often in modern weight-loss medicine. Semaglutide is the active ingredient in Wegovy and Ozempic. Tirzepatide is the active ingredient in Zepbound and Mounjaro.
The short answer: tirzepatide usually wins on average weight loss. Semaglutide still matters because it has a huge evidence base, specific cardiovascular and metabolic labels, and may be the better-covered or better tolerated option for some people.
For brand-specific searches, read Zepbound vs Wegovy and Ozempic vs Wegovy.
Quick Comparison
| Question | Semaglutide | Tirzepatide |
|---|---|---|
| Drug class | GLP-1 receptor agonist | Dual GIP / GLP-1 receptor agonist |
| Major brands | Wegovy, Ozempic, Rybelsus | Zepbound, Mounjaro |
| Weight-loss edge | Strong, but usually lower than tirzepatide in obesity comparisons | Highest average weight loss among approved injectable options |
| Diabetes use | Ozempic and Rybelsus are labeled for type 2 diabetes | Mounjaro is labeled for type 2 diabetes |
| Weight-management use | Wegovy is labeled for chronic weight management | Zepbound is labeled for chronic weight management |
| Main side effects | Nausea, vomiting, diarrhea, constipation, reflux and reduced appetite | Similar GI pattern; dose escalation is a common trouble point |
Mechanism
Semaglutide activates one main incretin pathway: GLP-1. That improves glucose-dependent insulin signaling, suppresses appetite, slows gastric emptying and reduces food intake.
Tirzepatide activates GLP-1 and GIP receptors. The added GIP pathway is one reason tirzepatide tends to produce larger average weight loss and strong A1c reductions in trials.
That does not mean tirzepatide is automatically better for every person. Contraindications, tolerability, drug access, insurance and medical history matter more than a trial average.
Weight Loss Data
| Comparison | Semaglutide result | Tirzepatide result | How to read it |
|---|---|---|---|
| Direct head-to-head obesity trial | SURMOUNT-5 reported about 13.7% average weight loss with semaglutide | SURMOUNT-5 reported about 20.2% average weight loss with tirzepatide | Tirzepatide had the clear average weight-loss advantage. |
| Pivotal obesity trials | STEP 1 reported about 14.9% average weight loss at 68 weeks | SURMOUNT-1 reported up to about 20.9% at 72 weeks | Different trials, but the pattern still favors tirzepatide on weight. |
| Practical conclusion | Still a strong approved weight-loss medicine | Often the stronger average weight-loss choice | Individual response and side effects can flip the real-world answer. |
Side Effects
Both drugs have a gastrointestinal side-effect profile:
- Nausea.
- Vomiting.
- Diarrhea.
- Constipation.
- Reflux, belching or appetite suppression that goes too far.
- Injection-site reactions.
Labels also warn about more serious risks, including pancreatitis signals, gallbladder problems, hypoglycemia when combined with insulin or insulin secretagogues, kidney injury in the setting of dehydration, and thyroid C-cell tumor warnings based on animal data.
For more detail, read GLP-1 side effects.
Which One Fits Which Case?
| Scenario | Usually points toward | Why |
|---|---|---|
| Highest average weight loss is the priority | Tirzepatide / Zepbound | Head-to-head and pivotal obesity data favor tirzepatide. |
| Established cardiovascular disease plus overweight or obesity | Often semaglutide / Wegovy | Wegovy has a specific cardiovascular risk-reduction label in this setting. |
| Type 2 diabetes | Ozempic or Mounjaro | Both are diabetes products; coverage often decides. |
| Obstructive sleep apnea with obesity | Zepbound | Zepbound has a label in this obesity-related condition. |
| Bad nausea during escalation | Neither automatically | The answer may be slower titration, holding a dose, switching or stopping under medical guidance. |
Bottom Line
For weight loss alone, tirzepatide is usually the stronger bet on average. For specific cardiometabolic labels, semaglutide can still be the more relevant medicine. For diabetes, the practical choice is often whichever labeled product is covered, tolerated and appropriate for the patient.
Use peptides for weight loss for the broader category map and the peptide database for structured compound pages.
FAQ
Is tirzepatide better than semaglutide for weight loss?
On average weight loss in obesity trials, tirzepatide generally performs better than semaglutide. SURMOUNT-5 directly compared tirzepatide with semaglutide and favored tirzepatide.
Is semaglutide safer than tirzepatide?
Both share the same dominant gastrointestinal side-effect pattern. Safety depends on the person, dose escalation, contraindications, other medicines and the exact product label.
Is tirzepatide a GLP-1?
Tirzepatide activates GLP-1 receptors and GIP receptors. It is usually discussed with GLP-1 medicines, but technically it is a dual GIP/GLP-1 receptor agonist.
Which is better for diabetes, Ozempic or Mounjaro?
Both are approved for type 2 diabetes. Mounjaro often produces larger A1c and weight changes on average, but coverage, tolerability and clinician judgment decide the practical choice.
Can you switch from semaglutide to tirzepatide?
Switching is common, but dose conversion is not simple. It should be handled by a prescriber because side effects and titration matter.
References
Aronne LJ, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. New England Journal of Medicine.
Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine.
Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine.
Novo Nordisk. Wegovy prescribing information.
Eli Lilly. Zepbound prescribing information.
Filed under